GEVO

http://www.prweb.com/releases/...tic_biology_market/prweb12542547.htm

Expanding Application Areas to Drive Growth in the Global Synthetic Biology Market, According to a New Report by Global Industry Analysts, Inc.

GIA announces the release of a comprehensive global report on Synthetic Biology. The global market for Synthetic Biology is projected to reach US$16.8 billion by 2020, driven by expanding commercial applications in end-use sectors such as energy, medicine, environment, agriculture and chemicals.


Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
.
Synthetic Biology: A Global Strategic Business Report

San Jose, California (PRWEB) February 25, 2015

Follow us on LinkedIn – Global interest in synthetic biology is driven by the technology’s promised potential to change society by bringing about a fundamental shift in the way energy, food and other industrial products are produced. In the field of healthcare, synthetic biology flaunts the potential to radically alter the way in which diseases are detected, prevented and cured. Synthetic biology is defined as engineered biology focused on the development of artificial, biologically inspired systems. In medical science, synthetic biology refers to the design and development of new biological organisms based on artificially created DNAs to design and develop new organisms or biochemical systems. This revolutionary branch of science brings together multiple disciplines such as computer modeling, engineering and biological sciences for creating next-generation biological systems, parts and devices.

Rapid advancements in DNA sequencing and synthesis are helping foster growth in the market. Computational modeling, DNA synthesis, and DNA sequencing, represent few of the major technologies that are playing key instrumental roles in pushing synthetic biology into the next stage of evolution. Commercial gene synthesis tools and pre-designed synbio tools are finding acceptance among molecular cloners. Synthetic biology based food ingredients are witnessing rapid commercialization, supported by the shifting focus on synbio ingredients in the global food supply chain.

Several of the leading chemical, energy, pharmaceutical, food, forestry and agribusiness companies are investing in synthetic biology research to develop new and potent products. Energy & Chemicals represents the largest as well as the fastest growing end-use market. Synthetic biology is opening new avenues for the scientific community to convert low-cost feedstock such as amino acids and sugars into fuels and medicines. The success of Genetically Modified (GM) seeds has opened up numerous opportunities for synthetic biology, with leading players in the sector investing substantial resources in developing a range of crops featuring enhanced nutritional value and pest protection. Additional applications in the area of agriculture include the development of new eco-friendly pesticides.

As stated by the new market research report on, Synthetic Biology, Europe represents the largest market worldwide, supported by high R&D interest in developing synthetic biology based products. Within Europe, Germany and the UK remain prominent markets. Asia-Pacific is forecast to emerge as the fastest-growing market with a projected CAGR of 41.9% over the analysis period.

Major players covered in the report include Agilent Technologies Inc., Amyris Inc., BP PLC, Chromatin Inc., Gevo Inc., 454 Life Sciences, Epoch Life Science Inc., Evolva SA, Solazyme Inc., Synthetic Genomics Inc., Synthetic Biologics Inc., DNA2.0, and Intrexon Corp, among others.

The research report titled "Synthetic Biology: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of trends, drivers, issues, and strategic industry activities of major companies worldwide. The report provides market estimates and projections for geographic markets such as the US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, and Rest of Europe), Asia-Pacific and Rest of World. The report analyzes the global market for synthetic biology by the following end-use sector - Energy & Chemicals, Biotechnology & Pharmaceuticals, and Others.

For more details about this comprehensive market research report, please click here

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes 1500+ full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/
 

http://www.nasdaq.com/symbol/gevo/real-time

As many as 2 brokerage firms have rated Gevo Inc (NASDAQ:GEVO) at 1. Research Analysts at Zacks have ranked the company at 3, suggesting the traders with a rating of hold for the short term. 2 analysts rated the company as a strong buy.

Gevo, Inc. (NASDAQ:GEVO) should head towards $1.78 per share according to 3 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $1 per share. The higher price estimate target is at $2 according to the Analysts.

Gevo, Inc. (NASDAQ:GEVO) was among the losers of the day with the shares closing down 0.009 points or 3.47%. The pessimistic mood was evident in the counter which never went considerably beyond the opening level of $0.259. The peak price level was $0.27 while the lowest was $0.24. However, a letup in the selling intensity helped the stock rebound to $0.25. The previous close of the counter is $0.259. The 52-week high of the stock is $1.55 while the yearly low is $0.1198. According to the latest information available, the market cap of the company is $33 million.

 

 
Gevo, Inc., is a renewable chemicals and advanced biofuels company. The Company is focused on the development and commercialization of alternatives to petroleum-based products. The Company operates in two segments: Gevo, Inc. Segment and Gevo Development/Agri-Energy Segment. Gevo, Inc. Segment is responsible for all research and development activities related to the future production of isobutanol, maintaining and protecting its intellectual property portfolio, developing future markets for its isobutanol and providing corporate oversight services. Its Gevo Development/Agri-Energy Segment is responsible for the production of ethanol and related products. In September 2010, the Company acquired a 22 MGPY ethanol production facility in Luverne, Minnesota that the Company intends to retrofit to produce isobutanol. Shares of Gevo, Inc. (NASDAQ:GEVO) appreciated by 17.9% during the past week but lost 6.9% on a 4-week basis. The shares have outperformed the S&P 500 by 17.16% in the past week but underperformed the index by 9.48% in the last 4 weeks.








by Taboola

Sponsored Li  

was da mit dem Kurs los ist :-D hoch runter ...rechts links :-D  

http://www.nasdaq.com/symbol/gevo/real-time  

geduld wird sich hier auszahlen. Hab meine Stück für den Long Run gesichert.  

könnten wir die .30$ antasten  

"...Gevo Sells Renewable Jet Fuel to NASA

ENGLEWOOD, Colo., March 9, 2015 (GLOBE NEWSWIRE) -- Gevo, Inc. (Nasdaq:GEVO), announced today that the National Aeronautics and Space Administration (NASA) has purchased Gevo's renewable Alcohol-to-Jet fuel (ATJ) for aviation use at the NASA Glenn Research Center in Cleveland, OH. Gevo's ATJ is manufactured at its demonstration biorefinery located in Silsbee, TX, using renewable isobutanol produced at its Luverne, MN, isobutanol plant. The biorefinery, where Gevo also produces bio-paraxylene and bio-isooctane, is operated in conjunction with South Hampton Resources.

Since its founding, NASA has been dedicated to the advancement of aeronautics and space technologies. Over the past several years, NASA has been studying the effects of alternate biofuels on engine performance, emissions and aircraft-generated contrails at altitudes typically flown by commercial airliners. Results from recent tests showed that a blend of renewable jet fuel and standard jet fuel significantly reduced emissions, as compared to using standard jet fuel alone, while not affecting flight operations.

"Gevo's patented ATJ fuel is a true drop-in fuel, designed to be fully compliant with aviation fuel specifications and provide equal performance, including fit-for-purpose properties and engine compatibility," said Dr. Patrick Gruber, Gevo's chief executive officer. "It is exciting to be working with NASA, a true leader in innovation worldwide."..."

"Through testing initiatives, partners such as Lufthansa and the U.S. military are looking to certify our ATJ and accelerate its full-scale commercialization. ATJ from Gevo's isobutanol is a clean burning, homegrown, drop-in jet fuel enabling a route to deliver aviation biofuels at scale and at a competitive cost," Gruber added.

http://ir.gevo.com/...?c=238618&p=irol-newsArticle&ID=2023808  

schöne news um mehr Aufmerksamkeit für diesen Titel zu bekommen.  

http://www.bayern-innovativ.de/fls2015?

Über 900 Experten aus Industrie und Wissenschaft haben bereits ihre Teilnahme zum "Forum Life Science" zugesagt.

Unter anderem von Unternehmen wie Aeskulap, AlzChem, ANiMOX,  apceth, Ascenion, AstraZeneca, Axolabs, BASF, Bayer, Beiersdorf, Beneo, Betagro, Biobased Industry Consortium, Biocrates, BioKryo, bioMérieux, Biomol, Bio-Rad Laboratories, Bioregeneration, Bioskinco, Biovariance, Biozoon, BRAIN, Cascat, Celabor, CellTool, Cfm Oskar Tropitzsch, Clariant, c-LEcta, Corbion, Creative Instruments, Curasan, Daiichi Sankyo, Definiens, Deutsche Lufthansa, DLR, Dust Biosolutions, Eckes-Granini, ethris, European Protein, Eurofins Medigenomix, evocatal, Evonik, Eyen, FGen, Fidura, freshDetect, Fritzmeier Umwelttechnik, Fuchs Europe Schmierstoffe, 4Gene, Genelux, GranMalt, GlaxoSmithKline, HiPP, Hochland, Hopsteiner, Hyglos, Imevax, IMGM Laboratories, ImmunoQure, Inamed, Infoteam, InSphero, Ireks, Iris Biotech, J. Rettenmeier & Söhne, Klifovet, Lohmann & Rauscher, Lonza, Lophius Biosciences, Martin Bauer, Mechatronic, Medigene, Metabolomic Discoveries, Merck, Metanomics Health, MicrobEnergy, MicroPyros, MIG, Mologen, MorphoSys, Nestlé, Northwest Biotherapeutics, Novamont, Novartis, Numares, Nutricia, OrganoBalance, ParticleMetrix, Perkin Elmer, PharmaZell, Procter & Gamble, Protina, Provenion, Qiagen, RealTVac, Roche, Salus, Sandoz, Sanofi-Aventis, Sarstedt, Sirion Biotech, siTOOLs, Südzucker, Susteen Technologies, Thermo Fisher Scientific, Toplab, U3 Pharma, Ugichem, Venneos, VTU Engineering, Wacker Chemie, Wyatt und
Forschungsinstituten und öffentlichen Einrichtungen aus Bayreuth, Berlin, Bern, Braunschweig, Bremerhaven, Brüssel, Dresden, Dortmund, Düsseldorf, Erlangen, Freising, Hamburg, Hohenheim, Innsbruck, Jülich, Laval (CA), Leipzig, Leuna, Linz, München, Regensburg, Rudolstadt, Straubing, Stuttgart, Weihenstephan, Wien, Würzburg sowie aus Belgien, Japan, Kanada und Thailand.



Neueste Erkenntnisse und Entwicklungen in den Life Sciences sowie ihre Umsetzung in innovative Technologien und neuartige Produkte in Bereichen wie Pharma, Ernährung und  Biotechnologie werden im Mittelpunkt des 9. Internationalen Kongresses „Forum Life Science" am 11./12. März 2015 an der TU München in Garching stehen.

In den parallelen Vortragsreihen „Pharma Development", „Food & Nutrition" und „Industrial Biotechnology" werden 80 Referenten aus 10 Ländern Trends, Strategien und neueste Forschungsergebnisse präsentieren.

Im Rahmen der Plenarsitzung wird der von Roche gestiftete und mit 50.000 Euro dotierte German Life Science Award verliehen. Die Gesellschaft für Biochemie und Molekularbiologie (GBM) und Roche haben gemeinsam diese Auszeichnung für begabte Nachwuchsforscher ausgelobt.

Der von der Bayern Innovativ GmbH konzipierte und organisierte Kongress ist  zentraler Treffpunkt und die Plattform für den Austausch von Informationen und den Aufbau branchenübergreifender Kontakte in den Life Sciences.

Teilnehmerstruktur "Forum Life Science":
 

Denke das wir hier heute wieder, nachdem gestern auf Teufel komm raus versucht wurde den Kurs zu bashen (ihub), in den Bereich .35 - .40$ kommen können.  

... "tolle" News gestern gewesen sein ...
GRUEBEL und GRINS ...
laugh...laugh...laugh...  

Und Stänkereien gehören hier nicht her.  

... mit der "Herrlichkeit" von GEVO !!!
(s. heutiger Kurs, der immer Recht hat !)  

einer der schlechtesten seit langem  

was ist denn da passiert, wieso so hart down in deutschland?  

steht doch zu 0.26 im BID zu Stuttgart. Alles easy. Drüben auf ihub hat das gebashe auch gestoppt, somit dürfte GEVO heute wieder up gehen. Charttechnik beachten! Uptrend in vollem Gange.  

sieht mir eher nach rücksetzer heute aus...lief ja gestern auch erst mega heiß um sich dann langsam abzukühlen...  

 

geht schon wieder UP im PreMarket  

http://seekingalpha.com/article/...-release-is-nice-but-issues-remain  

Wer sich auf SeekingAlpha beruft gehört meiner Meinung nach vom Börsenparkett geworfen. Die werden für Klicks pro Seite bezahlt - was meint ihr wie die wohl schreiben xD  

das egal ob gute oder schlechte Nachrichten, man sollten alle Infos überall her bekommen. Ob man danach handelt ist wieder ne andere Sache. Aber Börse ist halt ein Informationsgeschäft  

Ich lach mich schlapp ...
GRINS ...  

... und andere Boards (auch hier in Dtschld.) werden NICHT nach KLICKS bezahlt ???
GRINS uuuuuuuund einen
gaaaaaaaaaaaaaaaaaaaaanz großen KEEEEEEEEEEEEEKS for you !!!

Bittäschön........................

laugh ... laugh ... laugh ....  

Da sieht man mal wie wenig Ahnung du doch hast.